AstraZeneca PLC AZN NDX
Company Overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Why Investors Should Care
Generates a return on equity of 23.5%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 16.0%.
Net profit has compounded at 46.0% per year over the last five years.
Trades at a P/E of 24.8, below the sector median of 25.4.
Maintains a net profit margin of 17.2%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $58.74B (+8.6% YoY); net profit $10.22B.
- Trailing 12 Months Year-on-year growth — revenue +12.5%, earnings +5.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.8%, profit CAGR 46.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.82% |
| 1 Year: | 12.50% |
Compounded Profit Growth
| 5 Years: | 45.96% |
| 1 Year: | 5.30% |
Stock Price Performance
| 1 Year: | +16.65% |
| 6 Months: | -12.19% |
| 3 Months: | -18.66% |
| 1 Month: | -9.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross2d ago
- RSI (14)33.73 · Neutral
P/E of 24.81 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 23.5%.
- Profit CAGR of 46.0% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 8 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
| 9 | GILD Gilead Sciences, Inc. NDXSPX | 130.04 | 17.69 | $161.45B | 2.61% | 21.23% | 43.36% | 11.38% | 9.79% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 13.59B | 14.46B | 15.19B | 15.50B | 15.29B |
| Cost of Revenue | - | 2.24B | 2.47B | 2.80B | 3.12B | 2.68B |
| Gross Profit | - | 11.35B | 11.98B | 12.39B | 12.38B | 12.61B |
| Operating Expenses | - | 7.67B | 8.48B | 8.81B | 9.41B | 8.36B |
| Operating Income | - | 3.67B | 3.51B | 3.58B | 2.98B | 4.25B |
| EBITDA | - | 5.04B | 4.96B | 5.23B | 4.38B | 5.67B |
| Interest Expense | - | 349.00M | 439.00M | 434.00M | 484.00M | 393.00M |
| Pretax Income | - | 3.40B | 3.13B | 3.24B | 2.63B | 3.91B |
| Tax Provision | - | 481.00M | 679.00M | 709.00M | 300.00M | 833.00M |
| Net Income | - | 2.92B | 2.45B | 2.53B | 2.33B | 3.08B |
| Diluted EPS | 0.96 | 1.87 | 1.57 | - | 1.49 | 1.97 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 44.35B | 45.81B | 54.07B | 58.74B |
| Cost of Revenue | - | 12.39B | 8.27B | 10.21B | 10.63B |
| Gross Profit | - | 31.96B | 37.54B | 43.87B | 48.11B |
| Operating Expenses | - | 27.45B | 28.82B | 33.62B | 34.78B |
| Operating Income | - | 4.51B | 8.72B | 10.25B | 13.33B |
| EBITDA | - | 9.09B | 13.42B | 15.44B | 19.51B |
| Interest Expense | - | 1.33B | 1.59B | 1.68B | 1.61B |
| Pretax Income | - | 2.50B | 6.90B | 8.69B | 12.40B |
| Tax Provision | - | -792.00M | 938.00M | 1.65B | 2.17B |
| Net Income | - | 3.29B | 5.96B | 7.04B | 10.22B |
| Diluted EPS | - | 2.11 | 3.81 | 4.50 | 6.54 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 96.48B | 101.12B | 104.03B | 114.07B |
| Current Assets | - | 22.59B | 25.05B | 25.83B | 28.72B |
| Cash & Equivalents | - | 6.17B | 5.84B | 5.49B | 5.71B |
| Inventory | - | 4.70B | 5.42B | 5.29B | 6.56B |
| Receivables | - | 7.21B | 8.41B | 8.30B | 10.24B |
| Total Liabilities | - | 59.42B | 61.95B | 63.16B | 65.36B |
| Current Liabilities | - | 26.29B | 30.54B | 27.87B | 30.62B |
| Long Term Debt | - | 22.96B | 22.36B | 26.51B | 24.71B |
| Total Debt | - | 29.14B | 28.41B | 30.11B | 29.15B |
| Total Equity | - | 37.04B | 39.14B | 40.79B | 48.67B |
| Shares Outstanding | - | 1.55B | 1.55B | 1.55B | 1.55B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 9.81B | 10.35B | 11.86B | 14.57B |
| Investing Cash Flow | - | -2.96B | -4.06B | -7.98B | -6.81B |
| Financing Cash Flow | - | -6.82B | -6.57B | -4.00B | -7.54B |
| Capital Expenditure | - | -2.57B | -3.78B | -4.59B | -5.91B |
| Free Cash Flow | - | 7.24B | 6.57B | 7.28B | 8.67B |
| Net Change in Cash | - | 25.00M | -286.00M | -115.00M | 223.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 72.1% | 82.0% | 81.1% | 81.9% |
| Operating Margin % | - | 10.2% | 19.0% | 19.0% | 22.7% |
| Net Margin % | - | 7.4% | 13.0% | 13.0% | 17.4% |
| ROE % | - | 8.9% | 15.2% | 17.2% | 21.0% |
| ROCE % | - | 6.4% | 12.4% | 13.5% | 16.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Investor AB | 3.33% | 51.59M | $9.69B |
| 2 | Vanguard Capital Management LLC | 2.90% | 45.04M | $8.46B |
| 3 | Capital International Investors | 2.22% | 34.39M | $6.46B |
| 4 | FMR, LLC | 1.91% | 29.60M | $5.56B |
| 5 | Capital World Investors | 1.82% | 28.26M | $5.31B |
| 6 | Legal & General Group PLC | 1.67% | 25.85M | $4.85B |
| 7 | Wellington Management Group, LLP | 1.53% | 23.75M | $4.46B |
| 8 | Price (T.Rowe) Associates Inc | 1.26% | 19.49M | $3.66B |
| 9 | Bank of America Corporation | 1.23% | 19.06M | $3.58B |
| 10 | JPMORGAN CHASE & CO | 1.20% | 18.59M | $3.49B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AZN
AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug
In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon.
Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results
PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.
Amivantamab Lazertinib Forecast to Lead US EGFR NSCLC Therapy Revenue by 2036 as Post-TAGRISSO Competition Intensifies
Across the US, EU4, UK and Japan, opportunities center on post-osimertinib resistance, CNS disease and rare EGFR mutations; ADCs, bispecifics and next-gen TKIs face crowded competition.Dublin, July 14, 2026 (GLOBE NEWSWIRE) -- The "Epiderma…
Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape
Opportunities include integrating cardio-renal strategies, aligning therapies with real-world evidence, leveraging site-of-care economics, and enhancing supply resilience amid tariff influences. Late Stage Chronic Kidney Disease Therapeutic…
AstraZeneca to pay up to $1.5bn for global rights to lung cancer pill
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has agreed to pay $600 million upfront to secure worldwide rights to a lung cancer pill developed by China's Dizal Pharmaceutical. The Cambridge-based drugmaker could pay a further $900 million if the t…
Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy
Today, Dizal announced that it has entered into a global exclusive license agreement with AstraZeneca for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. A…
AZN — Frequently Asked Questions
What is the current share price of AstraZeneca PLC (AZN)?
As of 2026-07-14 21:23 PDT, AstraZeneca PLC (AZN) trades at $164.50 on NYSE. Its 52-week range is $135.08 to $208.62.
What is the market capitalisation of AZN?
AstraZeneca PLC (AZN) has a market capitalisation of $255.12B on NYSE.
What is the P/E ratio of AZN?
AZN trades at a trailing price-to-earnings (P/E) ratio of 24.81. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 5.85.
Does AZN pay a dividend?
AstraZeneca PLC (AZN) currently offers a dividend yield of 1.77%.
What is the return on equity (ROE) of AZN?
AZN has a return on equity (ROE) of 23.48%. Its return on capital employed (ROCE) is 15.97%.
Is AZN a good stock to buy?
This page provides a data-driven analysis of AstraZeneca PLC (AZN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.